Eduardo F Borba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/571674/publications.pdf

Version: 2024-02-01

147 papers

5,632 citations

71102 41 h-index 70 g-index

155 all docs

155 docs citations

155 times ranked 5748 citing authors

#	Article	IF	CITATIONS
1	The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus. Medicine (United States), 2004, 83, 1-17.	1.0	372
2	Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis and Rheumatism, 2005, 52, 1138-1147.	6.7	347
3	Circulating Follicular Helper–Like T Cells in Systemic Lupus Erythematosus: Association With Disease Activity. Arthritis and Rheumatology, 2015, 67, 988-999.	5.6	264
4	Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus, 1997, 6, 533-539.	1.6	241
5	Antimalarial treatment may have a timeâ€dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis and Rheumatism, 2010, 62, 855-862.	6.7	177
6	Major depressive disorder and disease activity in systemic lupus erythematosus. Comprehensive Psychiatry, 2007, 48, 14-19.	3.1	121
7	Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis and Rheumatism, 2000, 43, 1033.	6.7	116
8	Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 695-700.	4.8	111
9	Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. Lupus, 2005, 14, 938-946.	1.6	109
10	Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus, 2008, 17, 596-604.	1.6	108
11	Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus, 2012, 21, 1178-1182.	1.6	106
12	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Annals of the Rheumatic Diseases, 2015, 74, 1019-1023.	0.9	100
13	Gonad evaluation in male systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 2352-2361.	6.7	98
14	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq0 0 (</i>	O rgBT /Ove	erlock 10 Tf 50
15	Diseases, 2018, 77, 1549-1557. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal	0.9	89
	characteristics of 15 cases. Annals of the Rheumatic Diseases, 2007, 66, 740-746.		
16	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Annals of the Rheumatic Diseases, 2017, 76, 2071-2074.	0.9	89
17	Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2011, 70, 1068-1073.	0.9	87
18	Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus, 2007, 16, 350-354.	1.6	86

#	Article	IF	Citations
19	Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?. Lupus Science and Medicine, 2017, 4, e000213.	2.7	82
20	Systemic lupus erythematosus and "lupus dyslipoproteinemia― Autoimmunity Reviews, 2008, 7, 246-250.	5.8	81
21	Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Annals of the Rheumatic Diseases, 2011, 70, 2144-2147.	0.9	76
22	Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus, 2009, 18, 38-43.	1.6	67
23	Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2010, 16, 119-122.	0.9	67
24	Anti-lipoprotein lipase antibodies: A new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis and Rheumatism, 2004, 50, 3610-3615.	6.7	65
25	Testicular Sertoli cell function in male systemic lupus erythematosus. Rheumatology, 2008, 47, 1692-1697.	1.9	64
26	Mechanisms of Dyslipoproteinemias in Systemic Lupus Erythematosus. Clinical and Developmental Immunology, 2006, 13, 203-208.	3.3	63
27	Effectiveness of medialâ€wedge insole treatment for valgus knee osteoarthritis. Arthritis and Rheumatism, 2008, 59, 603-608.	6.7	63
28	Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus, 2007, 16, 273-278.	1.6	57
29	Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?. Rheumatology, 2012, 51, 1061-1069.	1.9	57
30	Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy. Clinical Rheumatology, 2014, 33, 505-509.	2,2	57
31	Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. Clinical Rheumatology, 2014, 33, 1093-1098.	2.2	56
32	Antibodies to ribosomal P proteins: A potential serologic marker for lupus membranous glomerulonephritis. Arthritis and Rheumatism, 2006, 54, 1568-1572.	6.7	55
33	The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics Classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary. Lupus, 2014, 23, 3-9.	1.6	54
34	Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus, 2015, 24, 536-545.	1.6	54
35	Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus, 2019, 28, 1101-1110.	1.6	51
36	Alveolar hemorrhage: distinct features of juvenile and adult onset systemic lupus erythematosus. Lupus, 2012, 21, 872-877.	1.6	50

#	Article	IF	CITATIONS
37	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology, 2012, 51, 1293-1298.	1.9	46
38	Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. Lupus, 2004, 13, 223-227.	1.6	45
39	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis and Rheumatology, 2019, 71, 411-419.	5 . 6	45
40	Exercise training can attenuate the inflammatory milieu in women with systemic lupus erythematosus. Journal of Applied Physiology, 2014, 117, 639-647.	2.5	44
41	Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. Europace, 2014, 16, 887-892.	1.7	44
42	Spontaneous tendon rupture in systemic lupus erythematosus: association with Jaccoud's arthropathy. Lupus, 2010, 19, 247-254.	1.6	43
43	Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Seminars in Arthritis and Rheumatism, 2016, 45, 675-683.	3.4	43
44	Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: Data from a Latin American cohort. Lupus, 2013, 22, 899-907.	1.6	42
45	Antiâ€ribosomal <scp>P</scp> protein: a novel antibody in autoimmune hepatitis. Liver International, 2013, 33, 909-913.	3.9	40
46	Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria?. Lupus, 2014, 23, 255-262.	1.6	40
47	Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?. Lupus, 2015, 24, 788-795.	1.6	39
48	Reduced Aerobic Capacity and Quality of Life in Physically Inactive Patients With Systemic Lupus Erythematosus With Mild or Inactive Disease. Arthritis Care and Research, 2016, 68, 1780-1786.	3.4	35
49	Consenso de lúpus eritematoso sistúmico. Revista Brasileira De Reumatologia, 2008, 48, 196-207.	0.8	35
50	Using exercise training to counterbalance chronotropic incompetence and delayed heart rate recovery in systemic lupus erythematosus: A randomized trial. Arthritis Care and Research, 2012, 64, 1159-1166.	3.4	34
51	Lipoprotein profile in limited systemic sclerosis. Rheumatology International, 2005, 25, 379-383.	3.0	33
52	Cutting-Edge Issues in Autoimmune Orchitis. Clinical Reviews in Allergy and Immunology, 2012, 42, 256-263.	6.5	33
53	Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors-data from a multi-ethnic Latin American cohort. Rheumatology, 2014, 53, 1431-1438.	1.9	33
54	Ovarian reserve in adult patients with childhood-onset lupus: a possible deleterious effect of methotrexate?. Scandinavian Journal of Rheumatology, 2014, 43, 503-511.	1.1	32

#	Article	IF	CITATIONS
55	Macrophage activation syndrome: A severe and frequent manifestation of acute pancreatitis in 362 childhood-onset compared to 1830 adult-onset systemic lupus erythematosus patients. Seminars in Arthritis and Rheumatism, 2016, 45, 706-710.	3.4	32
56	Eventos arrÃŧmicos no lúpus eritematoso sistúmico. Revista Brasileira De Reumatologia, 2010, 50, 81-89.	0.8	31
57	Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus, 2013, 22, 744-749.	1.6	30
58	Dieta e aspectos nutricionais no lúpus eritematoso sistúmico. Revista Brasileira De Reumatologia, 2012, 52, 395-408.	0.8	28
59	Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients. Lupus, 2010, 19, 27-33.	1.6	27
60	Penile anthropometry in systemic lupus erythematosus patients. Lupus, 2011, 20, 512-518.	1.6	27
61	PPAR \hat{I}^3 expression is increased in systemic lupus erythematosus patients and represses CD40/CD40L signaling pathway. Lupus, 2011, 20, 575-587.	1.6	27
62	Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis. Joint Bone Spine, 2008, 75, 416-421.	1.6	26
63	The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort. Lupus, 2012, 21, 1397-1404.	1.6	25
64	Increased Insulin Resistance and Glucagon Levels in Mild/Inactive Systemic Lupus Erythematosus Patients Despite Normal Glucose Tolerance. Arthritis Care and Research, 2018, 70, 114-124.	3.4	25
65	Impact of Distinct Therapies on Antibody Response to <scp>SARSâ€CoV</scp> â€2 Vaccine in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 562-571.	3.4	25
66	Myositis in mixed connective tissue disease: a unique syndrome characterized by immunohistopathologic elements of both polymyositis and dermatomyositis. Arquivos De Neuro-Psiquiatria, 2004, 62, 923-934.	0.8	24
67	Antibodies to ribosomal P proteins in lupus nephritis: A surrogate marker for a better renal survival?. Autoimmunity Reviews, 2011, 10, 126-130.	5.8	23
68	Serum adipocytokine profile and metabolic syndrome in young adult female dermatomyositis patients. Clinics, 2016, 71, 709-714.	1.5	23
69	The effects of exercise on lipid profile in systemic lupus erythematosus and healthy individuals: a randomized trial. Rheumatology International, 2015, 35, 61-69.	3.0	22
70	Pleuropulmonary involvement in patients with systemic lupus erythematosus from a Latin American inception cohort (GLADEL). Lupus, 2017, 26, 1368-1377.	1.6	22
71	Exercise Increases Insulin Sensitivity and Skeletal Muscle AMPK Expression in Systemic Lupus Erythematosus: A Randomized Controlled Trial. Frontiers in Immunology, 2018, 9, 906.	4.8	22
72	Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatology International, 2006, 26, 1078-1083.	3.0	21

#	Article	IF	Citations
73	Juvenile idiopathic arthritis activity and function ability: deleterious effects in periodontal disease?. Clinical Rheumatology, 2016, 35, 81-91.	2.2	21
74	Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. Journal of Rheumatology, 2019, 46, 1299-1308.	2.0	21
75	Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal. Lupus, 2009, 18, 1033-1052.	1.6	20
76	Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis. Clinics, 2011, 66, 1549-1552.	1.5	20
77	Abnormal chronotropic reserve and heart rate recovery in patients with SLE: a case–control study. Lupus, 2011, 20, 717-720.	1.6	20
78	Impact of Therapy on Metabolic Syndrome in Young Adult Premenopausal Female Lupus Patients: Beneficial Effect of Antimalarials. Arthritis Care and Research, 2015, 67, 1255-1262.	3.4	19
79	Primary antiphospholipid syndrome: absence of premature atherosclerosis in patients without traditional coronary artery disease risk factors. Lupus, 2016, 25, 472-478.	1.6	19
80	Increased arterial stiffness assessed by pulse wave velocity in Behçet's disease and its association with the lipid profile. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 454-459.	2.4	18
81	Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases. Advances in Rheumatology, 2019, 59, 17.	1.7	18
82	Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. Lupus, 2020, 29, 560-568.	1.6	18
83	Letter to the Editor. Lupus, 2004, 13, 618-620.	1.6	16
84	Serum uric acid levels are associated with lupus nephritis in patients with normal renal function. Clinical Rheumatology, 2018, 37, 1223-1228.	2.2	16
85	Ankylosing Spondylitis in a Patient With Primary Hypertrophic Osteoarthropathy. Journal of Clinical Rheumatology, 2007, 13, 175.	0.9	14
86	Lupus pleuritis: a relevant risk factor for pulmonary tuberculosis. Lupus, 2010, 19, 1585-1590.	1.6	14
87	The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. Lupus, 2021, 30, 554-559.	1.6	14
88	Dyslipidaemia in juvenile dermatomyositis: the role of disease activity. Clinical and Experimental Rheumatology, 2013, 31, 638-44.	0.8	14
89	Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 2022, 31, 974-984.	1.6	13
90	Complement-fixing activity of anticardiolipin antibodies in patients with and without thrombosis. Lupus, 2005, 14, 953-958.	1.6	11

#	Article	IF	CITATIONS
91	The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile-onset systemic lupus erythematosus. Lupus, 2005, 14, 613-617.	1.6	11
92	Digital vasculitis in systemic lupus erythematosus: a minor manifestation of disease activity?. Lupus, 2009, 18, 990-993.	1.6	11
93	Erratic control of breathing during exercise in patients with systemic lupus erythematosus: a pilot-study. Lupus, 2011, 20, 1535-1540.	1.6	11
94	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Seminars in Arthritis and Rheumatism, 2017, 47, 199-203.	3.4	11
95	Palindromic rheumatism associated with primary hypertrophic osteoarthropathy. Clinics, 2006, 61, 581-583.	1.5	11
96	Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy. Journal of Clinical Rheumatology, 2021, 27, S212-S216.	0.9	10
97	High prevalence of metabolic syndrome in antisynthetase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 241-247.	0.8	10
98	Impaired aerobic exercise capacity and cardiac autonomic control in primary antiphospholipid syndrome. Lupus, 2013, 22, 928-931.	1.6	9
99	Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients. Lupus, 2019, 28, 59-65.	1.6	9
100	Influência do estresse psicossocial no lúpus eritematoso sistêmico. Revista Brasileira De Reumatologia, 2004, 44, 355-361.	0.8	8
101	Quantifying subclinical central nervous lesions in primary antiphospholipid syndrome: The role of magnetization transfer imaging. Journal of Magnetic Resonance Imaging, 2008, 27, 483-488.	3.4	8
102	Autoimmune Orchitis., 2008,, 281-284.		8
103	Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus, 2017, 26, 73-83.	1.6	8
104	Is serum uric acid a predictor of long-term renal outcome in lupus nephritis?. Clinical Rheumatology, 2019, 38, 2777-2783.	2.2	8
105	SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy—ls there a link?. Nutrition, 2021, 85, 111115.	2.4	8
106	Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial. Clinical Rheumatology, 2021, 40, 2745-2751.	2.2	8
107	High-titer antichromatin antibody is associated with proliferative class IV of lupus nephritis. Clinical Rheumatology, 2008, 27, 1417-1421.	2.2	7
108	The Influence of Income and Formal Education on Damage in Brazilian Patients With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2017, 23, 246-251.	0.9	7

#	Article	IF	Citations
109	2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus. Clinical Rheumatology, 2022, 41, 1079-1085.	2.2	7
110	Suppurative thyroiditis due to aspergillosis: a case report. Journal of Medical Case Reports, 2014, 8, 379.	0.8	6
111	Plasma kinetics of an LDL-like non-protein nanoemulsion and transfer of lipids to high-density lipoprotein (HDL) in patients with rheumatoid arthritis. Journal of Clinical Lipidology, 2015, 9, 72-80.	1.5	6
112	ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?. Journal of Thrombosis and Thrombolysis, 2015, 40, 374-378.	2.1	5
113	Chronic low back pain and sick-leave: a functional magnetic resonance study. Advances in Rheumatology, 2020, 60, 46.	1.7	5
114	Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?. Lupus, 2021, 30, 1732-1738.	1.6	5
115	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. Advances in Rheumatology, 2021, 61, 60.	1.7	5
116	Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. PLoS Neglected Tropical Diseases, 2021, 15, e0010002.	3.0	5
117	Saúde reprodutiva em homens com lúpus eritematoso sistêmico. Revista Brasileira De Reumatologia, 2009, 49, .	0.8	4
118	Acute physical exercise is safe in patients with primary antiphospholipid syndrome with exclusive venous thrombosis and under oral anticoagulation with warfarin. Rheumatology International, 2014, 34, 1737-1741.	3.0	4
119	Carpal tunnel syndrome and prediabetes: Is there a true association?. Clinical Neurology and Neurosurgery, 2015, 137, 57-61.	1.4	4
120	Ozone decreases sperm quality in systemic lupus erythematosus patients. Revista Brasileira De Reumatologia, 2016, 56, 212-219.	0.7	4
121	Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis. Revista Brasileira De Reumatologia, 2015, 55, 1-21.	0.7	3
122	Increased corticotropin-releasing hormone (CRH) expression in cutaneous lupus lesions. Lupus, 2015, 24, 854-861.	1.6	3
123	Peliosis hepatis and systemic lupus erythematosus: A rare condition identified by magnetic resonance imaging. Revista Da Associação MÁ©dica Brasileira, 2018, 64, 19-21.	0.7	3
124	Adrenal steroidogenesis and ovarian reserve in adult childhood-onset systemic lupus erytematosus patients. Clinical Rheumatology, 2021, 40, 3651-3658.	2,2	3
125	Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. Lupus, 2021, 30, 1915-1922.	1.6	3
126	Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases. Vaccine: X, 2022, 10, 100131.	2.1	3

#	Article	IF	CITATIONS
127	Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease. Lupus, 2022, 31, 659-665.	1.6	3
128	Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression. Lupus, 2018, 27, 2215-2219.	1.6	2
129	Juvenile dermatomyositis: is periodontal disease associated with dyslipidemia?. Advances in Rheumatology, 2018, 58, 28.	1.7	2
130	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	1.6	2
131	Desvendando a sÃndrome antifosfolÃpide catastrófica (sÃndrome de Asherson). Revista Brasileira De Reumatologia, 2005, 45, 374-381.	0.8	2
132	Doença inflamatória intestinal com gangrena cutânea mimetizando a poliarterite nodosa. Revista Brasileira De Reumatologia, 2003, 43, 334-336.	0.8	1
133	Estudo longitudinal do anticorpo antilipoproteÃna lipase e sua relação com atividade de doença nos indivÃduos com lúpus eritematoso sistúmico sem anticorpos anti-dsDNA. Revista Brasileira De Reumatologia, 2009, 49, 39-47.	0.8	1
134	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus, 2020, 29, 1140-1145.	1.6	1
135	Avalia \tilde{A} § \tilde{A} £o dos fatores reprodutivos em 117 pacientes com esclerose sist \tilde{A} ªmica forma limitada e 72 pacientes com artrite reumat \tilde{A} 3ide. Revista Brasileira De Reumatologia, 2005, 45, 114-118.	0.8	1
136	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
137	Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort. Clinical and Experimental Rheumatology, 0, , .	0.8	1
138	P 021 Clinical-laboratorial study on a Brazilian population of Behçet's syndrome. Revue De Medecine Interne, 1993, 14, 64s.	1.0	0
139	A First Step Toward Solving the Neuropsychiatric Lupus Puzzle. Journal of Clinical Rheumatology, 1999, 5, 312-313.	0.9	0
140	The impact of <i>Arthritis </i> & <i>Rheumatism </i> in Latin America. Arthritis and Rheumatism, 2008, 58, S145-S145.	6.7	0
141	Les autoanticorps n'influent pas le développement des plaques d'athérome dans la polyarthrite rhumatoïde. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 596-601.	0.0	0
142	Medial-Wedge Insoles Improved Pain and Function in Osteoarthritic Knees with Valgus Deformity. Journal of Bone and Joint Surgery - Series A, 2009, 91, 493.	3.0	0
143	Herpes Zoster in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2012, 18, 225.	0.9	0
144	Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus. Lupus, 2021, 30, 096120332110203.	1.6	0

EDUARDO F BORBA

#	Article	IF	CITATIONS
145	Dislipidemia e aterosclerose no lúpus eritematoso sistêmico. Revista Brasileira De Reumatologia, 2003, 43, 324-328.	0.8	0
146	Colesterol e cloroquina. Revista Brasileira De Reumatologia, 2011, 51, 673-673.	0.8	0
147	Effect of a diet program on lipid and lipoproteins, body weight, nutrient intakes, and quality of life in patients with systemic lupus erythematosus. Journal of Rheumatology, 2003, 30, 1393-4; author reply 1394.	2.0	0